Novo Nordisk A/S Net debt/EBITDA
What is the Net debt/EBITDA of Novo Nordisk A/S?
The Net debt/EBITDA of Novo Nordisk A/S is -0.31
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on OTC compared to Novo Nordisk A/S
What does Novo Nordisk A/S do?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Companies with net debt/ebitda similar to Novo Nordisk A/S
- Bluestone Resources has Net debt/EBITDA of -0.32
- Oakdale Resources has Net debt/EBITDA of -0.31
- Spectur has Net debt/EBITDA of -0.31
- Boundary Gold and Copper Mining has Net debt/EBITDA of -0.31
- ITT has Net debt/EBITDA of -0.31
- Best Buy Co has Net debt/EBITDA of -0.31
- Novo Nordisk A/S has Net debt/EBITDA of -0.31
- Intermap Technologies has Net debt/EBITDA of -0.31
- Monarch Casino & Resort has Net debt/EBITDA of -0.31
- Canfor has Net debt/EBITDA of -0.30
- Leaf of Faith Beverage has Net debt/EBITDA of -0.30
- Keyware Technologies NV has Net debt/EBITDA of -0.30
- Equitable has Net debt/EBITDA of -0.29